Skip to main content

Table 2 Annual prevalence (2003–2008) of pharmacologically treated ADHD (methylphenidate, dexamfetamine and atomoxetine) by age category and gender

From: The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care

Age Category Year 2003 2004 2005 2006 2007 2008
Total Prevalence*1000 (Males and Females ≥ 6 years) 0.709 0.862 1.014 1.203 1.365 1.403
95% Cl (lb)*1000 0.676 0.825 0.975 1.161 1.320 1.358
95% Cl (ub)*1000 0.743 0.899 1.054 1.246 1.411 1.449
6-12 years
Female Prevalence*1000 1.339 1.642 2.042 2.310 2.775 2.769
95% Cl (lb)*1000 1.131 1.411 1.784 2.034 2.470 2.464
95% Cl (ub)*1000 1.574 1.900 2.327 2.613 3.108 3.101
Male Prevalence*1000 8.147 9.758 11.133 13.224 15.432 15.321
95% Cl (lb)*1000 7.634 9.195 10.532 12.566 14.716 14.607
95% Cl (ub)*1000 8.685 10.346 11.759 13.907 16.174 16.061
Total Prevalence*1000 4.825 5.795 6.688 7.886 9.241 9.181
95% Cl (lb)*1000 4.543 5.485 6.355 7.522 8.844 8.786
95% Cl (ub)*1000 5.121 6.119 7.034 8.262 9.651 9.590
13-17 years
Female Prevalence*1000 0.635 0.947 1.106 1.446 1.767 2.002
95% Cl (lb)*1000 0.465 0.742 0.890 1.201 1.497 1.714
95% Cl (ub)*1000 0.847 1.191 1.360 1.727 2.071 2.325
Male Prevalence*1000 6.250 7.535 9.104 11.027 11.752 12.569
95% Cl (lb)*1000 5.719 6.963 8.485 10.350 11.054 11.845
95% Cl (ub)*1000 6.818 8.141 9.757 11.737 12.483 13.325
Total Prevalence*1000 3.608 4.404 5.265 6.378 6.865 7.396
95% Cl (lb)*1000 3.314 4.087 4.925 6.008 6.484 6.999
95% Cl (ub)*1000 3.921 4.739 5.622 6.765 7.264 7.810
18-24 years
Female Prevalence*1000 0.118 0.116 0.112 0.244 0.337 0.335
95% Cl (lb)*1000 0.059 0.058 0.056 0.158 0.236 0.237
95% Cl (ub)*1000 0.211 0.207 0.200 0.361 0.466 0.460
Male Prevalence*1000 0.396 0.521 0.845 0.943 1.385 1.876
95% Cl (lb)*1000 0.283 0.391 0.679 0.770 1.178 1.637
95% Cl (ub)*1000 0.540 0.680 1.038 1.142 1.619 2.140
Total Prevalence*1000 0.263 0.327 0.493 0.607 0.878 1.122
95% Cl (lb)*1000 0.196 0.253 0.402 0.507 0.759 0.989
95% Cl (ub)*1000 0.346 0.417 0.599 0.721 1.010 1.267
25-45 years
Female Prevalence*1000 0.008 0.026 0.028 0.040 0.045 0.052
95% Cl (lb)*1000 0.002 0.012 0.014 0.023 0.027 0.032
95% Cl (ub)*1000 0.023 0.047 0.050 0.065 0.071 0.079
Male Prevalence*1000 0.025 0.038 0.052 0.074 0.095 0.105
95% Cl (lb)*1000 0.012 0.021 0.032 0.050 0.068 0.076
95% Cl (ub)*1000 0.046 0.062 0.079 0.105 0.130 0.141
Total Prevalence*1000 0.017 0.032 0.040 0.057 0.070 0.079
95% Cl (lb)*1000 0.009 0.021 0.027 0.042 0.053 0.061
95% Cl (ub)*1000 0.028 0.047 0.056 0.076 0.091 0.100
>45 years
Female Prevalence*1000 0.007 0.011 0.007 0.010 0.010 0.011
95% Cl (lb)*1000 0.002 0.004 0.002 0.004 0.004 0.005
95% Cl (ub)*1000 0.018 0.023 0.018 0.022 0.022 0.024
Male Prevalence*1000 0.008 0.008 0.015 0.015 0.020 0.027
95% Cl (lb)*1000 0.002 0.002 0.007 0.006 0.010 0.015
95% Cl (ub)*1000 0.020 0.020 0.030 0.029 0.036 0.044
Total Prevalence*1000 0.008 0.009 0.011 0.012 0.015 0.019
95% Cl (lb)*1000 0.003 0.004 0.006 0.007 0.009 0.012
95% Cl (ub)*1000 0.015 0.017 0.019 0.021 0.024 0.028
  1. CI (Confidence Interval), lb (lower boundary) and ub (upper boundary).